Pfizer’s new $214.8 million (€150m) biotechnology facility in Strangnas, Sweden was inaugurated yesterday, securing the country’s future in the company’s manufacturing network according to global manufacturing president Natale Ricciardi.
Demand for downstream processing products from biotechs drove the continued recovery of Millipore’s bioprocessing division in Q2 but operating income remained flat.
US biotechnology group OSI Pharmaceuticals will move HQ to a facility in Greenburgh, New York due, according to observers, to the high cost of land at its current base in Long Island.
Novartis and Jubilant Organosys are among several companies forced to recall generic drugs after manufacturing operations at their shared CMO, India’s MJ Biopharm, were found to be in breach of GMP guidelines.
BASF and Sinopec are to invest $1.4bn (€1bn) in expanding their Chinese specialty chemical joint venture, adding 10 plants and increasing capacity at three existing sites.
Novasep has bolstered its upstream processing capabilities by acquiring Henogen, a Belgium-based CMO that has biotech development and cGMP manufacturing expertise.
Millipore has ramped up capacity for its Mobius range of single use bio-processing and manufacturing technologies with a new purpose built production facility in Danvers, Massachusetts.
CMO Kemwell is receiving technical assistance from Boehringer Ingelheim for the construction of its new biotech facility, which is designed to marry European technology with Indian low cost manufacturing.
Wacker has brought its expanded cyclodextrin facility online following its $21m (€15m) expansion, which has significantly increased capacity in response to growing demand for the excipient.
CMO Richter-Helm BioLogics has achieved a 60 per cent increase in yield using technology from Upfront Chromatography, which demonstrated its system at BIO 2009.
in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.
HEM Pierre Vimont, Ambassador of France to the US, was at BIO 2009 talking about the measures his nation have taken to attract biotechs, including the introduction of the "most favourable R&D tax in Europe".
Agilent has completed the second expansion of its nucleic acid active pharmaceutical ingredient (API) manufacturing facility, which is intended to meet rising demand for oligonucleotide-based drugs.
Millipore has launched its single-use ChromaSorb membrane adsorber, which binds negative impurities from host cell protein (HCP), DNA, endotoxins, and viruses at high salt concentrations.
Drug delivery specialist Hospira has set up a “biologics clock” that counts the amount spent on cell culture-derived medications in the US in a bid to highlight the potential savings greater use of generics could provide.
AstraZeneca (AZ) has become the latest company to enter into a research collaboration with Jubilant, with the companies initially focusing on delivering preclinical candidates in the neuroscience area.
Althea Technologies’ biologics and injectables contract development, manufacturing and testing facility in San Diego, US is open for business, bringing to an end the firm’s two year campaign to expand capacity.
Massachusetts Biotechnology Council’s (MBC) 2015 strategic plan has outlined the difficulties the state faces in attracting biomanufacturing and called for increased focus on R&D.
The US contract manufacturing sector is strong enough to bounce back from any short-term slow down caused by the credit crisis, according to a new report by Frost & Sullivan (F&S).
Novozymes and Millipore have launched an animal-free culture supplement, which has been designed to reduce risk and regulatory pressures in upstream biopharmaceutical processes.
Flexibility is going to be a key driver for the pharmaceutical market in the next few years, according to Millipore's VP of downstream processing Paul Chapman.
Faced with a tougher operating environment, Irish drugmaker Elan has decided to slash staff numbers by 230 – or around 14 per cent of its total workforce – shelve the construction of a new biologics manufacturing facility and shutter fill-and-finish capacity...
Crucell and DSM Biologics have added fellow Dutch firm Bioceros to the PER.C6 vendor network to provide manufacturing and support capacity in line with increased demand for the cell line.
Dr Rajashekar Reddy, chief minister of Andhra Pradesh, India presided over the inauguration ceremony for Biological E’s new INR3bn ($61m) vaccine and biopharmaceuticals manufacturing campus.
Late last week the US Department of Health and Human Services (HHS) awarded Novartis a $490m contract to continue work on its cell-culture influenza vaccine plant in Holly Springs, North Carolina, US. in-PharmaTechnologist spoke with Novartis spokesman...
Positive noises from an FDA panel on GTC Biotherapeutics’ recombinant antithrombin ATryn may further the use of transgenic animals for drug production but should the manufacturing process rather than the drug’s safety be our prime concern?
The completion of trial batches of Siga Technologies’ smallpox treatment ST-246 could not have been better timed following as it does the recomendation that the Obama government raise the threat of bio-terror up its list of concerns.
Biotech bodies from around the globe have been calling on their respective governments to provide stimulus packages to compensate for the current difficulties in obtaining credit.
Irish drugmaker Elan, which recently dropped plans to sell its Elan Drug Technologies operation, has announced job cuts and the closure of offices in a bid to save cash.
Pall Life Sciences has launched its Allegro 3D biocontainers, which have been designed to improve the performance of the company’s large-scale, single use manufacturing systems.
The challenges in establishing a regulatory pathway for biogenerics were discussed at a recent FTC roundtable, with a FDA official saying in most cases it will be “impossible” to establish that the APIs are identical.
The possible sell-off of Enzon Pharmaceuticals’ biotechnology drugs business has come under fire by one of the firm’s shareholders, DellaCamera Capital Management, which says it is opposed to the move.
A Terre Haute, US resident has filed a lawsuit against Pfizer alleging that the company “negligently or recklessly” maintained its dam, resulting in the release of PCB.
Taiwan’s efforts to position itself as a major biotechnology hub received a further boost today with the opening of Merck KGaA’s dedicated technology training centre in Xizhi City, Taipei County.
Sartorius Stedim Biotech (SSB) and Bayer Technology Services (BTS) have signed an exclusive cooperation agreement for the manufacture and marketing of UVivatec products.
The European Parliament has voted in favour of incorporating the United Nations’ (UN) Globally Harmonised System (GHS) for chemical packaging into EU law.
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Premier Pneumatics, GE Healthcare and WaterSep.
Agilent and Millipore have formed a collaboration to develop fully validated chromatin immunoprecipitation (ChIP) microarray kits that will improve productivity and streamline epigenetic analysis.
Abraxis has licensed rights to use ProMetic’s protein technology in the development of four new biopharmaceuticals that it hopes will generate around $600m (€422.5m) in US sales.
in-PharmaTechnologist.com’s latest round up of developments in contract manufacturing includes Therapure’s launch and facility expansions by Hollister-Stier, West and Dow.
UCB is moving forward with efforts to focus on CNS disorders and immunology and plans to cut around 2,000 jobs as part of its SHAPE restructuring program.
Applied Biosystems (ABI) has developed a sequencing-based tool for gene expression analysis that can detect even minute amounts of previously unknown RNA transcripts.
An increase in the sale of vaccines such as Quinvaxem and Epaxal, helped Dutch drugmaker Crucell reduce its loss some 56 per cent to €7.9m ($12.5m) in the second quarter.
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Millipore, Sensor Products and Aspex.
Lonza is to co-develop and manufacture Novartis' biological pipeline as part of a long term strategic partnership that has been struck between the companies.
The PER.C6 cell culture-based antibody production platform has
achieved a new record yield of 27 grams of IgG antibody per litre,
bettering the 15 gram per litre mark that was reported earlier in
the year.
